Selumetinib in the treatment of non-small-cell lung cancer.

about

Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.Implications of KRAS mutations in acquired resistance to treatment in NSCLC.

P2860

Q48522177-2B428EC1-233B-4C9F-AD63-BC1A939E38EA Q49787333-33C38764-84F8-4A0D-AFF6-98EAB5806585

P2860

Selumetinib in the treatment of non-small-cell lung cancer.

Item

http://www.wikidata.org/entity/Q38836927

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Selumetinib in the treatment of non-small-cell lung cancer.

@en

type

Item

label

Selumetinib in the treatment of non-small-cell lung cancer.

@en

prefLabel

Selumetinib in the treatment of non-small-cell lung cancer.

@en

P1476

Selumetinib in the treatment of non-small-cell lung cancer.

@en

P2093

Ana Patrao

http://www.w3.org/2001/XMLSchema#string

Reyes Bernabé

http://www.w3.org/2001/XMLSchema#string

P2860

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.

Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.

Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.

P304

2545-2560

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON-2016-0132

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Fiona Blackhall

Emma Jane Dean

Louise Carter

P577

2016-07-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27467210

http://www.w3.org/2001/XMLSchema#string

Selumetinib in the treatment of non-small-cell lung cancer.

about

P2860

P2860

Selumetinib in the treatment of non-small-cell lung cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698